Colin G Leonard1, Vikram Padhye1, Ian J Witterick2. 1. Department of Otolaryngology, Head and Neck Surgery, University of Toronto, Toronto, Canada. 2. Department of Otolaryngology, Head and Neck Surgery, University of Toronto, Toronto, Canada. ian.witterick@sinaihealthsystem.ca.
Abstract
PURPOSE: The purpose of this review is to assess the recent evidence regarding the management of squamous cell carcinoma of the skull-base and to discuss the implications of these findings on clinical practice. METHOD: Free text Medline and MeSH term search of publications relating to Squamous Cell Carcinoma & Skull-base and Skull base, Neoplasm respectively. Multidisciplinary clinical guidelines were also reviewed. RESULTS: The primary search yielded a total of 271 papers which following initial review was reduced to 28. Secondary search yielded 56 papers. There were no randomised controlled trials relating to squamous cell carcinoma of the skull-base and as such this review is based on cohort studies, case series and expert opinion. CONCLUSION: Squamous cell carcinoma (SCC) is the most common cancer occurring in the Head and Neck. Squamous cell carcinoma is also the most common cancer arising within the nose and sinuses of which skull-base squamous cell carcinoma is a rare subgroup. Evidence relating to the management and survival of skull-base SCC is based on expert opinion and. retrospective analyses Clinical examination and biopsy, imaging and a broad multidisciplinary team are key to the management of skull-base SCC. The information gathered should be used to guide informed discussion by suitably trained experts with patients regarding surgical approach, post-operative recovery and adjuvant or neoadjuvant treatments. The standard of care is currently to perform skull base resection with or without additional craniotomy, pedicled or free flap reconstruction in multiple layers and post-operative radiation (usually photons or protons). Open approaches have traditionally been the mainstay, however in certain cases endoscopic approaches can yield equivalent results and offer many advantages. Despite advances in care survival remains poor with a nearly one in five risk of nodal recurrence within two years.
PURPOSE: The purpose of this review is to assess the recent evidence regarding the management of squamous cell carcinoma of the skull-base and to discuss the implications of these findings on clinical practice. METHOD: Free text Medline and MeSH term search of publications relating to Squamous Cell Carcinoma & Skull-base and Skull base, Neoplasm respectively. Multidisciplinary clinical guidelines were also reviewed. RESULTS: The primary search yielded a total of 271 papers which following initial review was reduced to 28. Secondary search yielded 56 papers. There were no randomised controlled trials relating to squamous cell carcinoma of the skull-base and as such this review is based on cohort studies, case series and expert opinion. CONCLUSION:Squamous cell carcinoma (SCC) is the most common cancer occurring in the Head and Neck. Squamous cell carcinoma is also the most common cancer arising within the nose and sinuses of which skull-base squamous cell carcinoma is a rare subgroup. Evidence relating to the management and survival of skull-base SCC is based on expert opinion and. retrospective analyses Clinical examination and biopsy, imaging and a broad multidisciplinary team are key to the management of skull-base SCC. The information gathered should be used to guide informed discussion by suitably trained experts with patients regarding surgical approach, post-operative recovery and adjuvant or neoadjuvant treatments. The standard of care is currently to perform skull base resection with or without additional craniotomy, pedicled or free flap reconstruction in multiple layers and post-operative radiation (usually photons or protons). Open approaches have traditionally been the mainstay, however in certain cases endoscopic approaches can yield equivalent results and offer many advantages. Despite advances in care survival remains poor with a nearly one in five risk of nodal recurrence within two years.
Authors: Valerie J Lund; Heinz Stammberger; Piero Nicolai; Paolo Castelnuovo; Tim Beal; Alfred Beham; Manuel Bernal-Sprekelsen; Hannes Braun; Paola Cappabianca; Ricardo Carrau; Luigi Cavallo; George Clarici; Wolfwang Draf; Felice Esposito; Juan Fernandez-Miranda; Wytske Fokkens; Paul Gardner; Verena Gellner; Henrik Hellquist; Phillipe Hermann; Werner Hosemann; David Howard; Nick Jones; Mark Jorissen; Amin Kassam; Daniel Kelly; Senta Kurschel-Lackner; Samuel Leong; Nancy McLaughlin; Roberto Maroldi; Amir Minovi; Michael Mokry; Metin Onerci; Yew Kwang Ong; Daniel Prevedello; Hesham Saleh; Dharambir S Sehti; Daniel Simmen; Carl Snyderman; Auturo Solares; Magaret Spittle; Aldo Stamm; Peter Tomazic; Matteo Trimarchi; Frank Unger; Peter-John Wormald; Adam Zanation Journal: Rhinol Suppl Date: 2010-06-01
Authors: Ian Ganly; Snehal G Patel; Bhuvanesh Singh; Dennis H Kraus; Giulo Cantu; Dan M Fliss; Luiz P Kowalski; Carl Snyderman; Jatin P Shah Journal: Cancer Date: 2010-09-24 Impact factor: 6.860
Authors: Paul A Gardner; Amin B Kassam; William E Rothfus; Carl H Snyderman; Ricardo L Carrau Journal: Otolaryngol Clin North Am Date: 2008-02 Impact factor: 3.346
Authors: James K Liu; David Decker; Steven D Schaefer; Augustine L Moscatello; Richard R Orlandi; Martin H Weiss; William T Couldwell Journal: Neurosurgery Date: 2003-11 Impact factor: 4.654
Authors: Ana Kober N Leite; Gustavo Fernandes de Alvarenga; Sérgio Gonçalves; Alexandre Bezerra Dos Santos; Hugo Sterman Neto; Claudio R Cernea; Marco Aurélio V Kulcsar; Luiz Paulo Kowalski; Leandro Luongo Matos Journal: Clinics (Sao Paulo) Date: 2021-05-21 Impact factor: 2.365